0000950170-24-060767.txt : 20240515
0000950170-24-060767.hdr.sgml : 20240515
20240515203257
ACCESSION NUMBER: 0000950170-24-060767
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240513
FILED AS OF DATE: 20240515
DATE AS OF CHANGE: 20240515
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Maduck Sean
CENTRAL INDEX KEY: 0001698310
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50679
FILM NUMBER: 24953300
MAIL ADDRESS:
STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED
STREET 2: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC
CENTRAL INDEX KEY: 0001088856
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770487658
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650.688.8803
MAIL ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
ownership.xml
4
X0508
4
2024-05-13
0001088856
CORCEPT THERAPEUTICS INC
CORT
0001698310
Maduck Sean
C/O CORCEPT THERAPEUTICS INCORPORATED
149 COMMONWEALTH DRIVE
MENLO PARK
CA
94025
false
true
false
false
See Remarks
true
Common Stock
2024-05-13
4
M
false
50000
3.88
A
135222
D
Common Stock
2024-05-13
4
S
false
50000
28.00
D
85222
D
Common Stock
10000
I
See Footnote
Common Stock
10000
I
See Footnote
Stock option (right to buy)
3.88
2024-05-13
4
M
false
50000
0.00
D
2026-02-26
Common Stock
50000
41986
D
Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
Fully exercisable.
President, Corcept Endocrinology
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck
2024-05-15